Spots Global Cancer Trial Database for amyloidosis
Every month we try and update this database with for amyloidosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis | NCT04392960 | AL Amyloidosis | [18F]Florbetabe... | 18 Years - | IRCCS Policlinico S. Matteo | |
| Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | NCT02909036 | Multiple Myelom... Amyloidosis | Melphalan Pegfilgrastim Autologous Hema... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis | NCT02816476 | Amyloidosis | Daratumumab | 18 Years - | University Hospital, Limoges | |
| Screening for Systemic Amyloidosis Via the Ligamentum Flavum | NCT03923920 | Amyloid Amyloidosis Spinal Stenosis Transthyretin A... Primary Amyloid... | Biopsy | 50 Years - | The Cleveland Clinic | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | NCT05283993 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm... | No intervention | - | Peking University First Hospital | |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | NCT05199337 | Amyloidosis AL Amyloidosis | ZN-d5 | 18 Years - | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | |
| Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | NCT01383759 | Light Chain Dep... Light Chain and... Monoclonal Immu... Amyloidosis | Bortezomib/Dexa... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | NCT02245867 | Amyloidosis | Chimeric Fibril... | 21 Years - | Columbia University | |
| Comprehensive Frailty Assessment | NCT02033928 | Myeloma, Multip... Paraproteinemia... Hematologic Neo... | 18 Years - | Ohio State University Comprehensive Cancer Center | ||
| Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis | NCT00607581 | Amyloidosis | cyclophosphamid... lenalidomide dexamethasone | 18 Years - | IRCCS Policlinico S. Matteo | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | NCT05283993 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm... | No intervention | - | Peking University First Hospital | |
| Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis | NCT03130348 | Amyloidosis Immunoglobulin ... | Bortezomib Dexamethasone Ibrutinib Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial | NCT02207556 | Primary Systemi... | Doxycycline | 18 Years - | Medical College of Wisconsin | |
| Vinorelbine and Gemcitabine in Myeloma | NCT02791373 | Multiple Myelom... Amyloidosis | Vinorelbine Gemcitabine | 18 Years - 75 Years | Insel Gruppe AG, University Hospital Bern | |
| Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | NCT05635266 | Age-Related Mac... Allergies Alpha-Gal Syndr... Alzheimer Disea... Amyloidosis Ankylosing Spon... Arthritis Alopecia Areata Asthma Atopic Dermatit... Autism Autoimmune Hepa... Behcet's Diseas... Beta-Thalassemi... Cancer Celiac Disease Kidney Diseases COPD Crohn Disease Cystic Fibrosis Diabetes Dravet Syndrome DMD Fibromyalgia Graves Disease Thyroid Disease... Hepatitis Hidradenitis Su... ITP Leukemia ALS Lupus or SLE Lymphoma Multiple Sclero... Myasthenia Grav... Heart Diseases Parkinson Disea... Pemphigus Vulga... Cirrhosis Psoriasis Schizophrenia Scleroderma Sickle Cell Dis... Stroke Ulcerative Coli... Vasculitis Vitiligo | Specimen sample | 18 Years - 85 Years | Sanguine Biosciences | |
| A Registry of AL Amyloidosis (ReAL) | NCT04839003 | AL Amyloidosis | 18 Years - 99 Years | IRCCS Policlinico S. Matteo | ||
| Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed | NCT01194791 | Primary Systemi... | Lenalidomide Cyclophosphamid... Dexamethasone | 18 Years - | PETHEMA Foundation | |
| Quality of Life (QOL) Registry for Patients With AL Amyloidosis | NCT02574676 | AL Amyloidosis Amyloidosis | non-interventio... | 18 Years - | Prothena Biosciences Ltd. | |
| Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis | NCT03431896 | Amyloidosis Amyloid Amyloid Neuropa... Amyloid Cardiom... Amyloid - Prima... Transthyretin A... AL Amyloidosis | - | The Cleveland Clinic | ||
| Registry for Adults With Plasma Cell Disorders (PCD's) | NCT03717844 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | NCT00919139 | Multiple Myelom... Smoldering Myel... Waldenstrom's M... Monoclonal Gamm... Amyloidosis | biologic sample... | - | SWOG Cancer Research Network | |
| APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | NCT04942067 | Multiple Myelom... Amyloidosis | APG-2575+ Pd APG-2575 + DRd | 18 Years - | Ascentage Pharma Group Inc. | |
| Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | NCT01383759 | Light Chain Dep... Light Chain and... Monoclonal Immu... Amyloidosis | Bortezomib/Dexa... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Registry of AL Amyloidosis (ReAL) | NCT04839003 | AL Amyloidosis | 18 Years - 99 Years | IRCCS Policlinico S. Matteo | ||
| Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | NCT02245867 | Amyloidosis | Chimeric Fibril... | 21 Years - | Columbia University | |
| Vinorelbine and Gemcitabine in Myeloma | NCT02791373 | Multiple Myelom... Amyloidosis | Vinorelbine Gemcitabine | 18 Years - 75 Years | Insel Gruppe AG, University Hospital Bern | |
| A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis | NCT00890552 | Leukemia Amyloidosis | Lenalidomide Melphalan Dexamethasone | 18 Years - | Stanford University | |
| Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry | NCT05556928 | Multiple Myelom... Amyloidosis Plasma Cell Leu... | 50 Years - | University of Alabama at Birmingham | ||
| A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | NCT03959358 | Multiple Myelom... Amyloidosis | Lenalidomide Pomalidomide | 18 Years - | University Health Network, Toronto | |
| Ixazomib Rollover Study | NCT02924272 | Multiple Myelom... Lymphoma Amyloidosis | Ixazomib | 18 Years - | Takeda | |
| Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis | NCT00607581 | Amyloidosis | cyclophosphamid... lenalidomide dexamethasone | 18 Years - | IRCCS Policlinico S. Matteo | |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) | NCT05260203 | Multiple Myelom... Solitary Plasma... Amyloidosis Chronic Myeloid... Chronic Lymphoc... T Cell Non-Hodg... Lymphocytic Lym... Hodgkin Lymphom... B-cell Non Hodg... Acute Myeloid L... Myelodysplasia Chronic Myelopr... Treatment Adher... Treatment Adher... | RITA (App) | 18 Years - | Advice Pharma Group srl | |
| Autologous Stem Cell Rescue for Primary Amyloidosis | NCT00186407 | Amyloidosis Blood and Marro... | high dose chemo... | 18 Years - 75 Years | Stanford University | |
| APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | NCT04942067 | Multiple Myelom... Amyloidosis | APG-2575+ Pd APG-2575 + DRd | 18 Years - | Ascentage Pharma Group Inc. | |
| Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis | NCT00166413 | Amyloidosis | CC-5013 | 18 Years - | Mayo Clinic | |
| Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis | NCT00607581 | Amyloidosis | cyclophosphamid... lenalidomide dexamethasone | 18 Years - | IRCCS Policlinico S. Matteo | |
| Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis | NCT03130348 | Amyloidosis Immunoglobulin ... | Bortezomib Dexamethasone Ibrutinib Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography | NCT03779815 | Multiple Myelom... | [18F]Florbetabe... | 19 Years - | Ulsan University Hospital | |
| Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | NCT04984330 | Amyloid Amyloidosis AL Amyloidosis | Selinexor Dexamethasone | 18 Years - | Weill Medical College of Cornell University | |
| Ixazomib Rollover Study | NCT02924272 | Multiple Myelom... Lymphoma Amyloidosis | Ixazomib | 18 Years - | Takeda | |
| Expanded Access to Venetoclax | NCT03123029 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu... | Venetoclax | - | AbbVie | |
| Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis | NCT01222260 | AL Amyloidosis | Bendamustine Dexamethasone | 18 Years - | Columbia University | |
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | NCT00919139 | Multiple Myelom... Smoldering Myel... Waldenstrom's M... Monoclonal Gamm... Amyloidosis | biologic sample... | - | SWOG Cancer Research Network | |
| A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis | NCT02545907 | Amyloidosis | Carfilzomib Thalidomide Dexamethasone | 18 Years - | University College, London | |
| Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis | NCT00224393 | Primary Systemi... | Enbrel | 18 Years - | The Cleveland Clinic | |
| Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | NCT01548573 | Multiple Myelom... | Dexamethasone Tandem autologo... Cisplatin Doxorubicin Cyclophosphamid... Etoposide Bortezomib Thalidomide Melphalan | 18 Years - 80 Years | University of Iowa | |
| Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis | NCT00166413 | Amyloidosis | CC-5013 | 18 Years - | Mayo Clinic | |
| Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | NCT01998503 | Amyloidosis | Bortezomib dexamethasone filgrastim autologous hema... Melphalan | 18 Years - 65 Years | Nanjing University School of Medicine | |
| Expanded Access to Venetoclax | NCT03123029 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu... | Venetoclax | - | AbbVie | |
| Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis | NCT02716103 | Amyloidosis | blood collectio... bone marrow col... | 18 Years - | Boston Medical Center | |
| Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis | NCT00224393 | Primary Systemi... | Enbrel | 18 Years - | The Cleveland Clinic | |
| Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | NCT02909036 | Multiple Myelom... Amyloidosis | Melphalan Pegfilgrastim Autologous Hema... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy | NCT05066607 | AL Amyloidosis | Isatuximab | 18 Years - | Intergroupe Francophone du Myelome | |
| Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis | NCT02555969 | Amyloidosis Primary Amyloid... | - | Tufts Medical Center | ||
| Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease | NCT02158052 | Multiple Myelom... Amyloidosis | Tacrolimus Equine Anti-thy... Kidney transpla... Bone marrow tra... Total body irra... | 18 Years - 65 Years | Massachusetts General Hospital | |
| Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | NCT01998503 | Amyloidosis | Bortezomib dexamethasone filgrastim autologous hema... Melphalan | 18 Years - 65 Years | Nanjing University School of Medicine | |
| Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis | NCT02555969 | Amyloidosis Primary Amyloid... | - | Tufts Medical Center | ||
| Registry for Adults With Plasma Cell Disorders (PCD's) | NCT03717844 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Allo SCT in Amyloidosis Non-interventional Study | NCT02257905 | AL Amyloidosis | 18 Years - 60 Years | European Society for Blood and Marrow Transplantation | ||
| Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry | NCT05556928 | Multiple Myelom... Amyloidosis Plasma Cell Leu... | 50 Years - | University of Alabama at Birmingham | ||
| B-Receptor Signaling in Cardiomyopathy | NCT01135849 | Carcinomas Amyloidosis Anal Cancer Anemia Cholangiocarcin... Transitional Ce... Bone Marrow Tra... Bone Cancer Cancer of Brain... Breast Cancer Carcinoma of th... Endocrine Cance... Esophageal Canc... Eye Cancer Gall Bladder Ca... Gastric (Stomac... Gastrooesophage... Gastrointestina... Gynecologic Can... Head and Neck C... Hepatobiliary N... Kidney (Renal C... Leukemia Lung Cancer Hodgkin Disease Lymphoma, Non-H... Mesothelioma Multiple Myelom... Myelodysplastic... Neuroendocrine ... Myeloproliferat... Pancreatic Canc... Prostate Cancer Skin Cancer Soft Tissue Sar... Testicular Canc... Thymus Cancer Thyroid Cancer | - 40 Years | Stanford University | ||
| Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis | NCT00607581 | Amyloidosis | cyclophosphamid... lenalidomide dexamethasone | 18 Years - | IRCCS Policlinico S. Matteo | |
| Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant | NCT02589860 | Mucositis Multiple Myelom... Amyloidosis Oral Mucositis | Melphalan kinet... Oral bacterial ... Gene expression... | 18 Years - | Indiana University | |
| B-Receptor Signaling in Cardiomyopathy | NCT01135849 | Carcinomas Amyloidosis Anal Cancer Anemia Cholangiocarcin... Transitional Ce... Bone Marrow Tra... Bone Cancer Cancer of Brain... Breast Cancer Carcinoma of th... Endocrine Cance... Esophageal Canc... Eye Cancer Gall Bladder Ca... Gastric (Stomac... Gastrooesophage... Gastrointestina... Gynecologic Can... Head and Neck C... Hepatobiliary N... Kidney (Renal C... Leukemia Lung Cancer Hodgkin Disease Lymphoma, Non-H... Mesothelioma Multiple Myelom... Myelodysplastic... Neuroendocrine ... Myeloproliferat... Pancreatic Canc... Prostate Cancer Skin Cancer Soft Tissue Sar... Testicular Canc... Thymus Cancer Thyroid Cancer | - 40 Years | Stanford University | ||
| Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis | NCT00035334 | Secondary (AA) ... Rheumatoid Arth... Nephrotic Syndr... Familial Medite... Kidney Diseases Gastrointestina... | NC-503 (Anti-am... | 18 Years - | Bellus Health Inc. - a GSK company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
